The HOOK2 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for the functional study of the HOOK2 gene in human T lymphocytes. Generated by targeted disruption of the HOOK2 locus in Jurkat cells, this heterogeneous pool preserves genetic diversity, minimizing clonal artifacts. The product is validated for loss of HOOK2 protein and is optimized for use in advanced cell biology, immunology, and cancer research applications.
Jurkat cells are an immortalized CD4+ T-lymphocyte line originally derived from the peripheral blood of a 14-year-old male with acute T-cell leukemia. This well-established model is extensively used to investigate T-cell receptor signaling, immune response mechanisms, and leukemogenesis. The suspension growth, robust proliferative capacity, and genetic tractability of Jurkat cells make them an ideal host for CRISPR-based knockout experiments, enabling the dissection of endocytic trafficking and organelle dynamics in a hematopoietic context.
HOOK2 encodes hook microtubule-tethering protein 2, an adaptor that links membrane organelles to the dynein-dynactin motor complex for retrograde transport along microtubules. It directly interacts with HOOK1, HOOK3, dynactin complex components, and Rab GTPases including Rab5 and Rab7 on early and late endosomes, respectively. These interactions facilitate endosomal maturation, lysosome positioning, and autophagy. HOOK2 coordinates the movement of endosomes and other organelles, and its disruption impairs organelle distribution, endocytic recycling, and downstream targets such as EGFR trafficking.
In Jurkat T cells, intact HOOK2 function is critical for processes such as receptor recycling, cytotoxic granule secretion, and immunological synapse formation, all of which rely on precise organelle positioning. Loss of HOOK2 in this leukemia-derived model can elucidate how endosomal trafficking defects contribute to malignant transformation, altered signal transduction, and immune evasion. This system offers a unique platform to investigate the intersection of microtubule-based transport and T-cell pathology, including oncogenic signaling pathways.
Researchers can employ these HOOK2 knockout Jurkat cells in a range of assays: immunofluorescence staining for organelle markers (LAMP1, EEA1) to visualize distribution changes, Western blot for knockout validation, flow cytometry-based endocytosis assays using transferrin uptake, live-cell imaging of organelle movement, co-immunoprecipitation to assess interactions with dynactin and Rab proteins, and RNA-seq for pathway analysis. Migration and invasion assays further reveal functional consequences. These applications position the cell population as a valuable resource for studying endosomal trafficking, drug delivery mechanisms, cancer cell biology, and neurodegenerative diseases. For technical assistance, contact Ascent Research.
